HNGE vs OABI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HNGE and OABI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HNGE and OABI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Hinge Health is a digital musculoskeletal (MSK) care platform that provides physical therapy, pain management, and surgery prevention services through a combination of software, connected sensor hardware, and human care teams. The company's core offering combines a mobile and connected-sensor app with personalized exercise therapy programs, behavioral health support, and access to physical therapists, plus care navigation for surgery decisions. Customers are primarily large employers and health plans that purchase Hinge Health benefits for their members.

Full HNGE guide

OmniAb was spun out of Ligand Pharmaceuticals in November 2022 and sells access to antibody discovery technology rather than drugs. Its platform centres on transgenic animals engineered to produce human-sequence antibodies (OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniClic) plus the xPloration high-throughput single-cell screening system and an ion channel screening group acquired with Icagen. Partners license the platforms, run their own discovery campaigns, and owe OmniAb payments at defined points: an upfront or annual access fee, service and instrument revenue, clinical and regulatory milestones, and a royalty on eventual product sales. As of Q2 2026 there were ~110 active partners, ~425 active programs, ~34 of those in clinical development or already approved, eight of the ten largest pharma companies among the partner base, and roughly 98% of programs carrying contracted future economics. Management has cited more than ~$3B of total contracted milestone potential at an average royalty near ~3.4%.

Full OABI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HNGE drivers: Employer benefit penetration; Surgery prevention as ROI driver.
• OABI drivers: Clinical graduation across ~34 partner programs; Milestone revenue reaching operating breakeven.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Digital health categories are competitive with various platforms targeting MSK and other condition areas. For OABI, revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HNGE if you believe its drivers more; OABI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HNGE and OABI guides.

HNGE. Hinge Health's valuation reflects the digital health growth premium, the demonstrated category leadership in MSK, and the path-to-profitability story. As a recent IPO, valuation is sensitive to broader digital health sector sentiment and to quarterly progression toward profitability.

OABI. A ~12.8x multiple on ~$38M of trailing revenue is a platform multiple, not a biotech-pipeline multiple, and it reflects contracted future economics rather than current profit. Two figures pull against each other: the milestone line tripled year over year while the royalty line was ~$0.3M for the quarter, so the near-term earnings power comes from stage payments rather than product sales. Cash of ~$52M with essentially no debt and first-half operating burn of ~$2.2M means the balance sheet is not the pressing question at these levels; the timing of partner programs is.

Headline figures (approximate, early 2026): HNGE shows revenue (ttm) ~$400 million (estimated, post-IPO disclosure), operating margin Approaching breakeven; varies by quarter, net income (ttm) Modest GAAP loss; non-GAAP near breakeven, eps (ttm) Near zero; OABI shows revenue (ttm) ~$38M, q2 2026 revenue ~$13.4M, up from ~$3.9M a year earlier, 2026 revenue guidance ~$32M to ~$36M, net loss ~$5.9M in Q2 2026, ~$44M trailing twelve months.

HNGE and OABI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HNGE and OABI exposure against your real portfolio. It is not an investment adviser.